As­traZeneca’s next big can­cer drug linked to fal­si­fied pre­clin­i­cal da­ta; Har­mo­ny rais­es $270M, nabs de­vel­op­ment rights to nar­colep­sy drug

→ Re­trac­tion Watch re­ports that one piece of the pre­clin­i­cal puz­zle for the BTK drug acal­abru­ti­nib was fab­ri­cat­ed by a re­searcher at Ac­er­ta. This case in­volved a mouse mod­el of pan­cre­at­ic can­cer and an ab­stract that was pro­duced in 2015. That was the same year that As­traZeneca bought a ma­jor­i­ty stake in the com­pa­ny for up to $7 bil­lion. Just a few weeks ago this drug won break­through ther­a­py sta­tus at the FDA along with an ac­cel­er­at­ed re­view plan for its first ap­proval.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER